Nammi Therapeutics Awarded Grant by California Institute for Regenerative Medicine (CIRM)
Updated: Feb 9
The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative.
The CIRM Board awarded $3,999,113 to Dr. David Stover and Nammi Therapeutics to complete the manufacture and testing needed to gain FDA permission for a clinical trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM, a “masked immunocytokine,” binds to and kills the tumor by activating the immune system.
Recent Posts
See AllNammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and CEO of Nammi Therapeutics, and highlighted the most recent achie
Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in Southern California. Nammi Therapeutics will receive one year
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL 138AM is a Masked Immunocytokine targeting a masked interferon